HC Wainwright Reaffirms Buy Rating for Pyxis Oncology (NASDAQ:PYXS)

Pyxis Oncology (NASDAQ:PYXS – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Friday, Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright‘s target price suggests a potential upside of 343.21% from the stock’s current price.

A number of other research analysts have also issued reports on the company. Weiss Ratings upgraded Pyxis Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, November 16th. Wedbush cut their price target on Pyxis Oncology from $8.00 to $7.00 and set an “outperform” rating on the stock in a report on Friday, November 6th. William Blair upgraded Pyxis Oncology from a “market perform” rating to an “outperform” rating in a report on Friday. Wells Fargo & Company increased their price target on Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a research report on Wednesday, September 9th. Finally, Wall Street Zen upgraded Pyxis Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.71.

Check Out Our Latest Report on PYXS

Pyxis Oncology Stock Up 7.4%

Shares of PYXS stock opened at $1.80 on Friday. Pyxis Oncology has a 52 week low of $1.03 and a 52 week high of $5.55. The stock has a market capitalization of $215.90 million, a PE ratio of -1.39 and a beta of 1.41. The firm has a 50 day moving average of $2.13 and a two-hundred day moving average of $2.16.

Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03. Analysts expect that Pyxis Oncology will post -1.12 EPS for the current fiscal year.

Institutional Trading of Pyxis Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its holdings in shares of Pyxis Oncology by 221.6% in the 3rd quarter. Goldman Sachs Group Inc. now owns 147,598 shares of the company’s stock valued at $344,000 after acquiring an additional 101,698 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Pyxis Oncology during the 3rd quarter worth about $150,000. Empowered Funds LLC purchased a new stake in Pyxis Oncology during the third quarter worth approximately $219,000. Blue Owl Capital Holdings LP purchased a new stake in Pyxis Oncology during the third quarter worth approximately $2,330,000. Finally, Commonwealth Equity Services LLC lifted its stake in Pyxis Oncology by 14.8% during the third quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company’s stock worth $114,000 after purchasing an additional 6,295 shares during the last quarter. 39.07% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

(Get Free Report)

Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue. The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.

Further Reading

Analyst Recommendations for Pyxis Oncology (NASDAQ:PYXS)

Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.